Castlemans Disease – Presenting with Recurrent Pleuropericardial Effusions- Mimicking Tuberculosis

Castlemans Disease – Presenting with Recurrent Pleuropericardial Effusions- Mimicking Tuberculosis

Ishma Aijazi, Fadhil Mustafa Abdulla, Hanana Poolakamannil Arif, Rabia Farhan, Riham Elgaali Mohamed Abdelfattah.

Department of Internal medicine and department of Histopathology- Dubai hospital ; Dubai – U.A.E

Castleman disease (CD) is an uncommon heterogeneous group of lymphoproliferative disorders which can affect the lymph nodes of the neck, chest, abdomen and pelvis. It was first described by Castleman, in 1954, known as benign mediastinal lymph node hyperplasia, which was histologically similar to thymoma of unknown cause. [1] It is divided into unicentric (localized ) Castleman disease (UCD) and multicentric ( generalized) Castleman disease (MCD) based on the number of lymph nodes involved.
Castleman disease has varied presentations. Clinically it can present as localized masses, or localized lymph node enlargement. Symptoms can result from compression effects of the enlarged lymph nodes and in asymptomatic patients it can be an incidental finding on radiological imaging.
It can also present as diffuse lymphadenopathy with severe systemic symptoms . Rarely it presents with pleuro-pericardial effusions .
We present a case of a; young gentleman presenting with anorexia, weight loss and night sweats . He had large exudative pleural effusion with pericardial effusion leading to constrictive pericarditis .He was started on ATT empirically, which was later stopped due to poor response . Extensive radiological work revealed multi loculated pleural effusion and multiple lymph nodes in the axillary and cervical area . Excisional Biopsy of the lymph nodes revealed Castleman disease .

Keywords: Castleman disease , pleural effusion , Multi centric disease , human herpes Virus 8, multicentric disease.

Free Full-text PDF

How to cite this article:

Ishma Aijazi, Fadhil Mustafa Abdulla, Hanana Poolakamannil Arif, Rabia Farhan, Riham Elgaali Mohamed Abdelfattah. Castlemans Disease – Presenting with Recurrent Pleuropericardial Effusions- Mimicking Tuberculosis. International Journal of Case Reports, 2023, 7:284. DOI: 10.28933/ijcr-2022-12-2805ia

References:

1. Pinheiro VG, Fernandes GH, Cezar LC, Alves ND, Menezes DB. Castleman’s disease accompanied by pleural effusion. Jornal Brasileiro de Pneumologia. 2008;34:626-30.
2. Doerr CH, Allen MS, Nichols III FC, Ryu JH. Etiology of chylothorax in 203 patients. InMayo Clinic Proceedings 2005 Jul 1 [Vol. 80, No. 7, pp. 867-870]. Elsevier
3. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S, Lechowicz MJ. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease. Blood, The Journal of the American Society of Hematology. 2017 Mar 23;129[12]:1646-57.
4. Blankenship ME, Rowlett J, Lt CJ, Roth RS, Jones RE. Giant lymph node hyperplasia [Castleman’s disease] presenting with chylous pleural effusion. Chest. 1997 Oct 1;112[4]:1132-3.
5. Nishikori A, Nishimura MF, Nishimura Y, Otsuka F, Maehama K, Ohsawa K, Momose S, Nakamura N, Sato Y. Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease. International journal of molecular sciences. 2022 Sep 7;23[18]:10301.
6. Iwaki N, Fajgenbaum DC, Nabel CS, Gion Y, Kondo E, Kawano M, Masunari T, Yoshida I, Moro H, Nikkuni K, Takai K. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman disease. American Journal of Hematology. 2016 Feb;91[2]:220-6.
7. Van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, The Journal of the American Society of Hematology. 2018 Nov 15;132[20]:2115-24.
8. Peterson BA, Frizzera G. Multicentric Castleman’s disease: Benign lymphoproliferative disorders. InSeminars in oncology 1993 [Vol. 20, No. 6, pp. 636-647].
9. Salisbury JR. Castleman’s disease in childhood and adolescence: report of a case and review of literature. Pediatric pathology. 1990 Jan 1;10[4]:609-15.
10. Dham A, Peterson BA. Castleman disease. Current opinion in hematology. 2007 Jul 1;14[4]:354-9.
11. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol. 2005;129[1]:3-17.
12. Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. Journal of clinical pathology. 2007 Dec 1;60[12]:1350-7.
13. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, Van Marck E, Salmon D, Gorin I, Escande JP, Weiss RA. Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proceedings of the National Academy of Sciences. 1999 Apr 13;96[8]:4546-51.
14. Reynolds SP, Gibbs AR, Weeks R, Adams H, Davies BH. Massive pleural effusion: an unusual presentation of Castleman’s disease. European Respiratory Journal. 1992 Oct 1;5[9]:1150-3.
15. Gibbons CJ, Rosencrantz H, Posey LD, Watts CM. Angiofollicular lymphoid hyperplasia [Castleman’s tumor] resembling a pericardial cyst: differentiation by computerized tomography. The Annals of Thoracic Surgery. 1981 Aug 1;32[2]:193-6.
16. Stavridis GT, Lau J. Castleman’s disease arising from the. Eur J Cardio-thorac Surg. 1993;7:218-9.
17. Johkoh T, Müller NL, Ichikado K, Nishimoto N, Yoshizaki K, Honda O, Tomiyama N, Naitoh H, Nakamura H, Yamamoto S. Intrathoracic multicentric Castleman disease: CT findings in 12 patients. Radiology. 1998 Nov;209[2]:477-81.
18. Yu L, Shi M, Cai Q, Strati P, Hagemeister F, Zhai Q, Li L, Fang X, Li J, Sun R, Zhang S. A novel predictive model for idiopathic multicentric castleman disease: The International Castleman Disease Consortium Study. The Oncologist. 2020 Nov;25[11]:963-73.\
19. Dispenzieri A, Gertz MA. Treatment of Castleman’s disease. Current treatment options in oncology. 2005 May;6[3]:255-66.
20. Nishimoto N. Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan. Clinical reviews in allergy & immunology. 2005 Jun;28[3]:221-9.
21. Van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X. Siltuximab, a novel anti–interleukin-6 monoclonal antibody, for Castleman’s disease. Journal of clinical oncology. 2010 Aug 10;28[23]:3701-8.